Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 4/20 | 0.36 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16838682 | 0.84 | PIK3CG (0.41) | KDM4EALDH1A1ALOX15HSD17B10PIK3CG | |
| SCHEMBL20924540 | 0.77 | HCAR3 (0.46) | KDM4EALDH1A1ALOX15CES1FAAH | |
| SCHEMBL20239403 | 0.74 | — | — | |
| SCHEMBL8303534 | 0.72 | — | — | |
| SCHEMBL15200818 | 0.70 | CES1 (0.51) | CES1FAAHNLRP3HCAR2TDP1 | |
| SCHEMBL7977655 | 0.68 | — | — | |
| SCHEMBL1838907 | 0.68 | — | — | |
| SCHEMBL19556315 | 0.68 | — | — | |
| SCHEMBL567221 | 0.68 | CES1 (0.39) | KDM4EALDH1A1ALOX15PIK3CGHPGD | |
| SCHEMBL1912536 | 0.68 | PIK3CG (0.38) | KDM4EALDH1A1HSD17B10PIK3CGHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2021-09-21 | — | — | US | disclosed |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2019-01-03 | — | — | US | disclosed |
| US-10085989-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-10-02 | — | — | US | disclosed |
| EP-3083627-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS | NOVARTIS AG (CH) | 2018-09-05 | — | — | EP | disclosed |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-11-23 | — | — | US | disclosed |
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
| EP-3083627-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20160303129-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | disclosed |
| US-9303034-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| WO-2015095477-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
| US-20160303129-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
| US-10085989-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | KDM4E 3178/4885ALDH1A1 866/4885ALOX15 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.